GlassScriptPhysician profile
Matthew A Shaw
NPI 1952701518
$1,821.96
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,015 · 2020: $763 · 2021: $43.37.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $362.43 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $342.91 | 2019-2020 | |
| Lilly USA, LLC | $207.04 | 2019-2020 | |
| Novo Nordisk INC | $188.59 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $157.04 | 2019-2021 | |
| Pfizer INC. | $155.89 | 2019-2020 | |
| Amarin Pharma, INC. | $73.93 | 2020 | |
| Glaxosmithkline, LLC. | $71.39 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.13 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $36.76 | 2019 | |
| Antares Pharma, INC. | $35.45 | 2019 | |
| Merck Sharp & Dohme LLC | $34.89 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $24.36 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.91 | 2020 | |
| Assertio Therapeutics, INC. | $18.19 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $14.25 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.42 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.38 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Shaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.